Scancell Holdings plc is a biopharmaceutical company focused on the cancer therapeutics market. The Company's principal activity consists of the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer. The Company is developing a pipeline of immunotherapies for the treatment of cancer based on its ImmunoBody and Moditope platforms. The Company's products include SCIB1, SCIB2 and Modi-1. The Company's first cancer vaccine, SCIB1, is being developed for the treatment of melanoma and is in Phase I/II clinical trials. SCIB2 contains multiple T cell epitopes derived from the lung cancer associated antigen NY-ESO-1. It is developed to the point at which the product is defined and ready for further preclinical development as an immunotherapy for any tumor that expresses the NY-ESO-1 antigen. The Company's first Moditope development candidate is Modi-1. Modi-1 consists of two citrullinated vimentin peptides and one citrullinated enolase peptide.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: LON:SCLP
- CUSIP: N/A
- Web: www.scancell.co.uk/
- Market Cap: £33.35 million
- Outstanding Shares: 261,558,000
- 50 Day Moving Avg: GBX 12.37
- 200 Day Moving Avg: GBX 12.25
- 52 Week Range: GBX 9.68 - GBX 17.88
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: GBX 0.03 per share
- Price / Book: 4.25
- EBIDTA: ($3,770,000.00)
- Return on Equity: -37.54%
- Return on Assets: -35.30%
- Average Volume: 376,850 shs.
Frequently Asked Questions for Scancell Holdings Plc (LON:SCLP)
What is Scancell Holdings Plc's stock symbol?
Scancell Holdings Plc trades on the London Stock Exchange (LON) under the ticker symbol "SCLP."
Where is Scancell Holdings Plc's stock going? Where will Scancell Holdings Plc's stock price be in 2017?
1 equities research analysts have issued 12-month price objectives for Scancell Holdings Plc's shares. Their predictions range from GBX 68 to GBX 68. On average, they expect Scancell Holdings Plc's share price to reach GBX 68 in the next twelve months. View Analyst Ratings for Scancell Holdings Plc.
Who are some of Scancell Holdings Plc's key competitors?
Some companies that are related to Scancell Holdings Plc include NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Infinity Pharmaceuticals (INFI), Navidea Biopharmaceuticals (NAVB), Galectin Therapeutics (GALT), ReNeuron Group Plc (RENE), OvaScience (OVAS), Sunesis Pharmaceuticals (SNSS), Fibrocell Science (FCSC), Abzena PLC (ABZA), Bio-Path Holdings (BPTH), Aptose Biosciences (APTO), Prima BioMed Ltd (PBMD), Oncobiologics (ONS), Caladrius Biosciences (CLBS), Senomyx (SNMX), Cleveland BioLabs (CBLI) and AEterna Zentaris (AEZS).
Who are Scancell Holdings Plc's key executives?
Scancell Holdings Plc's management team includes the folowing people:
- Lindy Gillian Durrant, Chief Executive Officer, Executive Director
- Richard Morley Goodfellow Ph.D., Joint Chief Executive Officer, Executive Director, Commercial Director
- Sally Elizabeth Adams, Development Director, Director
- John C. Chiplin Ph.D., Non-Executive Chairman of the Board
- Katherine Cornish-Bowden, Non-Executive Director
- Matthew G.W. Frohn, Non-Executive Director
- Alan James Lewis Ph.D., Non-Executive Director
How do I buy Scancell Holdings Plc stock?
Shares of Scancell Holdings Plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Scancell Holdings Plc's stock price today?
MarketBeat Community Rating for Scancell Holdings Plc (LON SCLP)MarketBeat's community ratings are surveys of what our community members think about Scancell Holdings Plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Scancell Holdings Plc stock can currently be purchased for approximately GBX 12.75.
Consensus Ratings for Scancell Holdings Plc (LON:SCLP) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Buy Rating|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||GBX 68|
Analysts' Ratings History for Scancell Holdings Plc (LON:SCLP)
(Data available from 9/19/2015 forward)
|7/11/2017||Panmure Gordon||Reiterated Rating||Buy||GBX 68|
Earnings History for Scancell Holdings Plc (LON:SCLP)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Scancell Holdings Plc (LON:SCLP)
Current Year EPS Consensus Estimate: $-1.20 EPS
Dividend History for Scancell Holdings Plc (LON:SCLP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Scancell Holdings Plc (LON:SCLP)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Scancell Holdings Plc (LON:SCLP)
Latest Headlines for Scancell Holdings Plc (LON:SCLP)
Scancell Holdings Plc (SCLP) Chart for Tuesday, September, 19, 2017